Windtree Therapeutics, a Nasdaq-listed biotech firm, has announced plans to purchase up to $700 million in BNB, a significant cryptocurrency, following its recent all-time high. The company aims to integrate BNB into its balance sheet as part of a growing trend of publicly traded entities acquiring crypto assets beyond Bitcoin. Windtree is set to raise $520 million specifically for BNB purchases, following a prior commitment of $200 million. They will work alongside Kraken for custody of the assets. This move comes during a period where companies are exploring digital currencies to boost stock prices, as evidenced by the recent surge in stocks related to crypto investments, including Windtree’s own 162% increase over the past month. Notably, Windtree's CEO emphasized the necessity of these funds for their acquisition strategy. BNB, established by Binance, currently ranks as the fifth-largest cryptocurrency with a market cap of $106.9 billion, despite some price fluctuations.

Source đź”—